New mRNA flu shot enters early human testing

NCT ID NCT05945485

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage trial is testing a new mRNA flu vaccine in 50 healthy adults aged 18 to 49. The vaccine uses mRNA technology to target a specific flu strain. Researchers will compare its safety and immune response to a standard seasonal flu shot. The goal is to see if the new vaccine is safe and triggers a strong immune reaction.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

mRNA vaccine (DCVC H1 HA mRNA-LNP)

What this could lead to

If successful, this could lead to a new type of flu vaccine that is quicker to update and produce.

What could go wrong

This is a very early Phase 1 trial with only 50 people. The vaccine may not work as hoped, and side effects are still being studied.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for INFLUENZA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

influenza prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • University of Iowa - Infectious Disease Clinic

    Iowa City, Iowa, 52242, United States